Anzeige
Mehr »
Donnerstag, 22.05.2025 - Börsentäglich über 12.000 News
Neues Milliarden-Ziel im Kupfergürtel der Anden? Explorationspotenzial sprengt alle Erwartungen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D5YN | ISIN: US6031701013 | Ticker-Symbol:
NASDAQ
21.05.25 | 21:59
16,690 US-Dollar
0,00 % 0,000
1-Jahres-Chart
MINERALYS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
MINERALYS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur MINERALYS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiMineralys präsentiert Lorundrostat-Studiendaten auf der ESH 20252
DiMineralys to present lorundrostat trial data at ESH 20251
13.05.Mineralys plans NDA submission for lorundrostat following pivotal hypertension data and $201M equity raise1
12.05.Mineralys Therapeutics, Inc. - 10-Q, Quarterly Report2
MINERALYS THERAPEUTICS Aktie jetzt für 0€ handeln
12.05.Mineralys Therapeutics GAAP EPS of -$0.79 beats by $0.174
12.05.Mineralys Therapeutics, Inc. - 8-K, Current Report3
09.05.Uncovering Potential: Mineralys Therapeutics' Earnings Preview1
23.04.Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)1
01.04.ACC25: Mineralys' uncontrolled hypertension drug aces trial1
31.03.Stifel maintains Buy on Mineralys stock with $45 target1
31.03.Mineralys Therapeutics, Inc. - 8-K, Current Report2
29.03.Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ...247- Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile...
► Artikel lesen
25.03.Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March2
25.03.Mineralys Therapeutics, Inc.: Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET1
18.03.Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock1
17.03.Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American ...356RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
► Artikel lesen
12.03.Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session9
12.03.Mineralys Therapeutics prices $175M stock offering1
12.03.Mineralys Therapeutics sets $13.50 share price for public offering1
12.03.Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock241RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
► Artikel lesen
Seite:  Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1